Home » Our Pipeline1-1 » ADCT-402, Lonca

LEAD CANDIDATE

Loncastuximab Tesirine (Lonca)

Lonca is an ADC composed of a humanized monoclonal antibody that binds to human CD19 and conjugated through a linker to a PBD-dimer toxin. Once bound to a CD19-expressing cell, Lonca is internalized into the cell where enzymes release the PBD-based warhead.

CD19 is an ideal target for an ADC approach

CD19 is highly expressed in a range of B-cell hematological tumors, including certain types of lymphoma and leukemia, while its expression in healthy tissue is restricted.

Lonca is the focus of the LOTIS Clinical Development Program

In clinical trials, lead candidate Lonca has demonstrated significant single-agent clinical activity across a broad population of patients with relapsed or refractory diffuse large B-cell, mantle cell, and follicular lymphomas.

The clinical development of this product is ongoing. Loncastuximab Tesirine (ADCT0402) is an investigational agent. Safety and efficacy has not yet been established.

[402-101] – A Phase 1 Dose-escalation Study to Evaluate the Tolerability, Safety, Pharmacokinetics, and Antitumor Activity of ADCT-402 in Patients With Relapsed or Refractory B-cell Lineage Non Hodgkin Lymphoma (B-NHL)

NCT02669017
COMPLETE

[402-201] – A Phase 2 Open-Label Single-Arm Study to Evaluate the Efficacy and Saftey of Loncastuximab Tesirine in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

NCT03589469
ACTIVE/CLOSED TO RECRUITING

[402-103] – A Phase 1/2 Open-Label Study to Evaluate the Safety and Efficacy of Loncastuximab Tesirine and Ibrutinib in Patients With Advanced Diffuse Large B-Cell Lymphoma or Mantle Cell Lymphoma

NCT03684694
ACTIVE/RECRUITING

[402-104] – A Phase 1 Open-Label Study to Evaluate the Safety and Antitumor Activity of Loncastuximab Tesirine and Durvalumab in Patients With Advanced Diffuse Large B-Cell Lymphoma, Mantle Cell Lymphoma, or Follicular Lymphoma

NCT03685344
ACTIVE/CLOSED TO RECRUITING

[402-311] – A Phase 3 Randomized Study of Loncastuximab Tesirine Combined With Rituximab Versus Immunochemotherapy in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

NCT04384484
NOT YET RECRUITING

VIEW OUR RESEARCH

Our Vision

We strive to be a leading antibody drug conjugate company that transforms the lives of those impacted by cancer

Our Values

Integrity – ethical and authentic in our approach

Creativity – innovate with an entrepreneurial spirit

Accountability – ownership to drive results

Collaboration – partner for better outcomes

Urgency – act decisively and proactively

Being part of ADCT means you are dialed in to a unique and excing professional opportunity. One important way we demonstrate our commitment to you is through our comprehensive benefits programs.

Compensation & Rewards

Competitive salaries – regularly benchmarked
Bonuses – all ADCT employees are eligible for a discretionary bonus
401-K savings plan with a competitive employer match for US-based employees
Contributory pension for European-based employees
Employee Stock Purchase Plan
Annual Equity Grant
Employee Rewards & Recognition

Vacation, Holidays, Sick Leave, Health & Well-Being

We offer a competitive vacation and holiday package
Health Insurance: focusing on your and your family’s health is just as important as your work. ADCT offers a comprehensive beneﬁts package including group Medical, Dental, Vision and Disability coverage plans, Health Spending Accounts, and a variety of voluntary insurance products*
Global Wellness Program – ADCT offers a Global Wellness Education program and Global Employee Assistance beneﬁt to all employees, offering opportunities for employees to learn and practice impactful healthy habits
Hybrid working environment; opportunity to work remotely

Learning & Development

Development opportunities throughout your career at ADCT
Access to our comprehensive Learning Management System, providing opportunities for continuous learning and development

*Some benefits may vary based on the country location, eligibility guidelines, and local regulations.

Laurél Tasso, Executive Assistant

Hear colleagues extol the benefits of working at a small and nimble biotech company

Transcript

I did work for several years at large pharma, the thing about large pharma is you sometimes get lost as an employee number.
We have presence over the US and globally but leadership makes it feel like we’re all together in the same culture , so that I enjoy about this company.
This is a small company, has a small company start-up feel, it’s great to work with so many Innovative people who are good at what they do and are open to new ideas and challenging the status quo
You can work at larger pharmas where you blend in and not heard, you come to ADCT and if you’re motivated if you’re engaged you can really make a meaningful impact.
Working at a small biotech is certainly different than working at a large pharma organization I think some of the things I appreciate are the nimbleness.
At the end of the day that nimbleness and how we can react very quickly is a great thing for patients.
Really the camaraderie you get with your colleagues when working here, we all wear many hats, so it’s really exciting from a developmental prespective as well, not doing one thing and same thing every day, get to do lots of different things get experiences and exposure you
wouldn’t get at a larger company, but at same time we have the support systems that we need to get our job done, so it’s really like the best of both worlds.

Ana Varela, NJ Office Manager

Ana works tirelessly to help patients, even while battling breast cancer herself

Transcript

In 2019 I was diagnosed with stage 4 breast cancer, as anyone who’s been through these types diagnoses I know how devastating it is and how crushing it can be.
So being able to get on a targeted therapy like that does similar work that our drug would do brought a lot of hope into my life and I’m very grateful for that.
So this mission here is just personal I’m excited to bring hope to patients and their families.

Chief Business & Strategy Officer, David Gilman

Hear how David Gilman’s personal journey inspired him to join ADC Therapeutics

Transcript

I made a choice 25 years ago that vast majority of the work that I did was going to be oncology and cancer research.
I had at the time lost my fiancee to lung cancer at a young age and so you know, the tug at the heart string was pretty strong.
And it seemed like sort of the right sweet spot and company evolution that hopefully I could be helpful and have that sense of connection.
I have a tiny little piece in creating a drug that saves a life, even if it were just one.
That makes all the difference to me.

Leaving ADC Therapeutics
You are now leaving ADC Therapeutics’ site. ADC Therapeutics does not necessarily endorse the organization associated with this link and takes no responsibility for the content contained therein. This resource link is for informational purposes only. Do you want to continue to the external site and leave ADCTherapeutics.com?

LEAVE ADCTHERAPEUTICS.COMLEAVE ADCTHERAPEUTICS.COM

LEAD CANDIDATE

Loncastuximab Tesirine (Lonca)

CD19 is an ideal target for an ADC approach

Lonca is the focus of the LOTIS Clinical Development Program

The clinical development of this product is ongoing. Loncastuximab Tesirine (ADCT0402) is an investigational agent. Safety and efficacy has not yet been established.

VISION AND VALUES

Our Vision

Our Values

BENEFITS

Compensation & Rewards

Vacation, Holidays, Sick Leave, Health & Well-Being

Learning & Development

Laurél Tasso, Executive Assistant

Transcript

Ana Varela, NJ Office Manager

Transcript

Chief Business & Strategy Officer, David Gilman

Transcript